Veracyte (VCYT) Other Operating Expenses (2012 - 2026)

Veracyte (VCYT) has 15 years of Other Operating Expenses data on file, last reported at $27.7 million in Q1 2026.

• Quarterly Other Operating Expenses rose 10.6% year-over-year to $27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.8 million (up 23.08% YoY) and the FY2025 annual result came in at $123.2 million, up 20.63% from the prior year.
• Other Operating Expenses rose to $27.7 million in Q1 2026 per VCYT's latest filing, from $26.6 million in the prior quarter.
• The five-year high for Other Operating Expenses was $59.8 million in Q3 2023, with the low at -$64.6 million in Q4 2022.
• Average Other Operating Expenses over 5 years is $32.7 million, with a median of $27.7 million recorded in 2026.
• Year-over-year, Other Operating Expenses sank 227.81% in 2022 and surged 189.47% in 2023.
• Veracyte's Other Operating Expenses stood at -$64.6 million in 2022, then surged by 189.47% to $57.8 million in 2023, then sank by 50.93% to $28.4 million in 2024, then declined by 6.39% to $26.6 million in 2025, then advanced by 4.42% to $27.7 million in 2026.
• Business Quant data shows VCYT's Other Operating Expenses at $27.7 million in Q1 2026, $26.6 million in Q4 2025, and $25.1 million in Q3 2025.